CiplaCPLFY 94 Days Payable is 131.07 as of Mar. 2026, which is 30% above its 10-year median of 101.00. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Cipla ranks better than 64.03% on this metric.
Cipla's average Accounts Payable for the
three
months ended in Mar. 2026 was $347.98 Mil. Cipla's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $242.27 Mil.
Hence, Cipla's Days Payable for the
three
months ended in Mar. 2026 was 131.07.
The historical rank and industry rank for Cipla's Days Payable or its related term are showing as below:
CPLFY'
s Days Payable Range Over the Past 10 Years
Min: 90.46 Med: 101 Max: 116.79
Current: 115.98
During the past 13 years, Cipla's highest Days Payable was 116.79. The lowest was 90.46. And the median was 101.00.
CPLFY's Days Payable is ranked better than 64.03% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs CPLFY: 115.98
Cipla's Days Payable
increased
from Mar. 2025 (118.28) to Mar. 2026 (131.07).
It may suggest that Cipladelayed paying its suppliers.
Cipla Days Payable Related Terms
Cipla Days Payable Historical Data
* Premium members only.
The historical data trend for Cipla's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Days Payable distribution charts can be found below:
* The bar in red indicates where Cipla's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cipla's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (CPLFY) has a Days Payable of 131.07 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cipla and its competitors. This is 30% above median its historical median of 101.00. Over the past decade, Cipla's Days Payable has ranged from 90.46 to 116.79. According to the industry distribution chart, Cipla ranks #332 out of 923 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is Cipla's Days Payable too high?
Cipla's current Days Payable of 131.07 is 30% above median its 10-year median of 101.00. Over the past 10 years, this metric has ranged from a low of 90.46 to a high of 116.79. The Drug Manufacturers industry median Days Payable is 90.98. Cipla's value of 131.07 is 44.1% above this industry median. Based on the distribution chart, Cipla ranks #332 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #332 out of 923 companies for Days Payable. This puts Cipla in the upper half of its industry. The industry median Days Payable is 90.98. Cipla's value of 131.07 is 44.1% above this benchmark. Historically, Cipla's own Days Payable has ranged from 90.46 to 116.79 over the past decade. While the company's 10-year median is 101.00 vs. the industry median of 90.98, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current Days Payable of 131.07 is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Days Payable is 131.07, which is 30% above median its own 10-year median of 101.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current Days Payable of 131.07. The current Days Payable is 131.07, which is 30% above median its 10-year median of 101.00 and 44.1% above the Drug Manufacturers industry median of 90.98. Cipla's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cipla (CPLFY), the current Days Payable is 131.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 